Human Intestinal Tissue and Cultured Colonic Cells Contain Globotriaosylceramide Synthase mRNA and the Alternate Shiga Toxin Receptor Globotetraosylceramide
Open Access
- 1 November 2010
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 78 (11) , 4488-4499
Abstract
Escherichia coli O157:H7 and other Shiga toxin (Stx)-producing E. coli (STEC) bacteria are not enteroinvasive but can cause hemorrhagic colitis. In some STEC-infected individuals, a life-threatening sequela of infection called the hemolytic uremic syndrome may develop that can lead to kidney failure. This syndrome is linked to the production of Stx by the infecting organism. For Stx to reach the kidney, the toxin must first penetrate the colonic epithelial barrier. However, the Stx receptor, globotriaosylceramide (Gb3), has been thought to be absent from human intestinal epithelial cells. Thus, the mechanisms by which the toxin associates with and traverses through the intestine en route to the kidneys have been puzzling aspects of STEC pathogenesis. In this study, we initially determined that both types of Stx made by STEC, Stx1 and Stx2, do in fact bind to colonic epithelia in fresh tissue sections and to a colonic epithelial cell line (HCT-8). We also discovered that globotetraosylceramide (Gb4), a lower-affinity toxin receptor derived from Gb3, is readily detectable on the surfaces of human colonic tissue sections and HCT-8 cells. Furthermore, we found that Gb3 is present on a fraction of HCT-8 cells, where it presumably functions to bind and internalize Stx1 and Stx2. In addition, we established by quantitative real-time PCR (qRT-PCR) that both fresh colonic epithelial sections and HCT-8 cells express Gb3 synthase mRNA. Taken together, our data suggest that Gb3 may be present in small quantities in human colonic epithelia, where it may compete for Stx binding with the more abundantly expressed glycosphingolipid Gb4.Keywords
This publication has 61 references indexed in Scilit:
- Comparison of Binding Platforms Yields Insights into Receptor Binding Differences between Shiga Toxins 1 and 2Biochemistry, 2010
- Treatment options for HUS secondary to Escherichia coli O157:H7Kidney International, 2009
- TTP/HUS and prognosis: the syndrome and the disease(s)Kidney International, 2009
- Acute Renal Failure in ChildrenPediatrics in Review, 2008
- Differential intracellular transport and binding of verotoxin 1 and verotoxin 2 to globotriaosylceramide‐containing lipid assembliesJournal of Cellular Physiology, 2008
- The 13C4 Monoclonal Antibody That Neutralizes Shiga Toxin Type 1 (Stx1) Recognizes Three Regions on the Stx1 B Subunit and Prevents Stx1 from Binding to Its Eukaryotic Receptor GlobotriaosylceramideInfection and Immunity, 2006
- A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2Proceedings of the National Academy of Sciences, 2006
- Human Microvascular Endothelial Cells Are Strongly Sensitive to Shiga ToxinsBiochemical and Biophysical Research Communications, 1998
- Binding ofEscherichia coliverotoxins to cell surface protein on wild-type and globotriaosylceramide-deficient Vero cellsCanadian Journal of Microbiology, 1998
- Globotriosyl ceramide is specifically recognized by the escherichia coli verocytotoxin 2Biochemical and Biophysical Research Communications, 1988